Search Page

1

GBM radiosensitizers: dead in the water…or just the beginning?

Bindra RS, Chalmers AJ, Evans S, Dewhirst M. Bindra RS, et al. Among authors: Evans S. J Neurooncol. 2017 Sep;134(3):513-521. doi: 10.1007/s11060-017-2427-7. Epub 2017 Jul 31. J Neurooncol. 2017. PMID: 28762004 Review.

Cite

Share

2

Optimizing hypoxia detection and treatment strategies.

Koch CJ, Evans SM. Koch CJ, et al. Among authors: Evans SM. Semin Nucl Med. 2015 Mar;45(2):163-76. doi: 10.1053/j.semnuclmed.2014.10.004. Semin Nucl Med. 2015. PMID: 25704388 Free PMC article. Review.

Cite

Share

3

Efficacy of technology-based interventions to increase the use of hearing protections among adolescent farmworkers.

Khan KM, Evans SS, Bielko SL, Rohlman DS. Khan KM, et al. Among authors: Evans SS. Int J Audiol. 2018 Feb;57(2):124-134. doi: 10.1080/14992027.2017.1374568. Epub 2017 Sep 18. Int J Audiol. 2018. PMID: 28918682 Free PMC article. Clinical Trial.

Cite

Share

4

Pharmacokinetic and pharmacodynamic modifiers of EF5 uptake and binding.

Koch CJ, Evans SM. Koch CJ, et al. Among authors: Evans SM. J Nucl Med. 2015 Apr;56(4):653. doi: 10.2967/jnumed.114.151662. Epub 2015 Mar 5. J Nucl Med. 2015. PMID: 25745093 Free article. No abstract available.

Cite

Share

5

Feasibility of a low-cost hearing screening in rural Indiana.

Khan KM, Bielko SL, Barnes PA, Evans SS, Main ALK. Khan KM, et al. Among authors: Evans SS. BMC Public Health. 2017 Sep 18;17(1):715. doi: 10.1186/s12889-017-4724-7. BMC Public Health. 2017. PMID: 28923033 Free PMC article.

Cite

Share

6

Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients.

Evans SM, Putt M, Yang XY, Lustig RA, Martinez-Lage M, Williams D, Desai A, Wolf R, Brem S, Koch CJ. Evans SM, et al. J Neurooncol. 2016 Apr;127(2):391-400. doi: 10.1007/s11060-015-2051-3. Epub 2016 Jan 8. J Neurooncol. 2016. PMID: 26746692 Free PMC article.

Cite

Share

7

Biodegradable Polymersomes for the Delivery of Gemcitabine to Panc-1 Cells.

Sood N, Jenkins WT, Yang XY, Shah NN, Katz JS, Koch CJ, Frail PR, Therien MJ, Hammer DA, Evans SM. Sood N, et al. Among authors: Evans SM. Version 2. J Pharm (Cairo). 2013;2013:932797. doi: 10.1155/2013/932797. J Pharm (Cairo). 2013. PMID: 26167335 Free PMC article.

Cite

Share

8

Cumulative risk analysis of carcinogenic contaminants in United States drinking water.

Evans S, Campbell C, Naidenko OV. Evans S, et al. Heliyon. 2019 Sep 19;5(9):e02314. doi: 10.1016/j.heliyon.2019.e02314. eCollection 2019 Sep. Heliyon. 2019. PMID: 31687532 Free PMC article.

Cite

Share

9

Mechanisms of blood flow and hypoxia production in rat 9L-epigastric tumors.

Koch CJ, Jenkins WT, Jenkins KW, Yang XY, Shuman AL, Pickup S, Riehl CR, Paudyal R, Poptani H, Evans SM. Koch CJ, et al. Among authors: Evans SM. Tumor Microenviron Ther. 2013 Jan;1:1-13. doi: 10.2478/tumor-2012-0001. Tumor Microenviron Ther. 2013. PMID: 25436211 Free PMC article.

Cite

Share

10

Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients.

Koch CJ, Lustig RA, Yang XY, Jenkins WT, Wolf RL, Martinez-Lage M, Desai A, Williams D, Evans SM. Koch CJ, et al. Among authors: Evans SM. Transl Oncol. 2014 Dec;7(6):752-8. doi: 10.1016/j.tranon.2014.10.004. Transl Oncol. 2014. PMID: 25500085 Free PMC article.

Cite

Share